PolyNova CardioVascular LLC

Polynova Cardiovascular, Inc. is developing novel heart valve replacement technology using state-of-the-art synthetic biomaterials designed to displace existing animal tissue-based products being used in transcatheter aortic valve replacement (TAVR) procedures, which avoids open-heart surgery. Polynova aims to be the first company to commercialize safe and effective polymeric prosthetic heart valves.

Contact Information:

Danny Bluestein, Ph.D., CSO
Phone: 631-444-2156
Email: Danny.bluestein@stonybrook.edu